Patent 7427405 was granted and assigned to Idera Pharmaceuticals on September, 2008 by the United States Patent and Trademark Office.
The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.